AUTHOR=Shaik Mohammad Anjum , Banerjee Arpan , Bernstein Audrey M. TITLE=Ubiquitin-specific peptidase 10 as a context-dependent deubiquitination hub: integrating stress adaptation, disease progression, and therapeutic opportunities JOURNAL=Experimental Biology and Medicine VOLUME=Volume 251 - 2026 YEAR=2026 URL=https://www.ebm-journal.org/journals/experimental-biology-and-medicine/articles/10.3389/ebm.2026.11322 DOI=10.3389/ebm.2026.11322 ISSN=1535-3699 ABSTRACT=Ubiquitination is a reversible post-translational modification that regulates protein stability, localization, and signaling, while deubiquitinases provide dynamic control over ubiquitin-dependent protein fate. Among these enzymes, ubiquitin-specific peptidase 10 (USP10) has emerged as a highly context-dependent regulator of cellular homeostasis and disease. USP10 influences diverse biological processes, including tumor progression, fibrotic remodeling, mechanotransduction, mitochondrial quality control, metabolic adaptation, and cellular stress responses. Its biological effects are often divergent: in some settings, USP10 supports protective pathways by stabilizing wild-type p53, promoting AMPK-dependent metabolic checkpoints, preserving mitochondrial integrity, and enhancing stress adaptation. In chronic disease contexts it drives pathology by stabilizing oncogenic or profibrotic substrates, including mutant p53, β-catenin, YAP/TAZ, EIF4G1, integrins, and SMAD4. In chronic inflammatory microenvironments, USP10 reinforces disease-promoting signaling through the NEMO/NF-κB and S100A9-SYK-NLRP3 inflammasome axes, increasing inflammatory mediators such as TNF-α, IL-6, CCL2, S100A9, caspase-1/GSDMD, ROS, and profibrotic TGF-β/CTGF pathways. This review synthesizes the dual and context-specific functions of USP10 across cancer, fibrosis, mitochondrial dysfunction, and tissue injury. Rather than functioning as an intrinsically protective or pathogenic enzyme, USP10 acts as a molecular switch whose output is determined by substrate availability, interacting partners, subcellular localization, disease stage, and the surrounding signaling environment. Because accumulating evidence implicates USP10 as a driver of pathology in multiple chronic disease settings, we also examined emerging therapeutic strategies to inhibit USP10 activity, including small-molecule inhibitors, RNA interference approaches, and substrate-selective disruptors. Understanding the context-dependent biology of USP10 will be essential for developing therapeutic strategies that suppress its disease-promoting functions while preserving or enhancing its protective roles.